Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
— Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex
— Dr. Sandor brings more than 20 years of oncology clinical development experience, including leading programs to regulatory approval at Array BioPharma, Incyte and AstraZeneca
— Appointments strengthen the Board as Mestag evaluates MST-0312 in the Phase 1 STARLYS trial, currently enrolling patients with advanced solid tumors
Cambridge, UK, October 20, 2026 – Mestag Therapeutics (“Mestag”), a clinical-stage biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced the appointments of Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors.
